Endocrinology · Medical Literature
Efficacy of mindfulness-based interventions on psychological distress, hyperandrogenism, and metabolic profile in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Abstract
Polycystic ovary syndrome (PCOS) negatively impacts women's metabolic health, reproductive hormones, and psychological well-being. The aim of this study was to systematically evaluate the efficacy of mindfulness-based interventions (MBIs), such as yoga and mindfulness meditation, on anthropometric indices, metabolic profiles, reproductive hormones, and quality of life in women with PCOS. A systematic review and meta-analysis was conducted with 10 randomized controlled trials (RCTs) involving 356 participants, selected from databases including PubMed and Cochrane Library up to January 2025. Data were synthesized using Review Manager 5.3 to calculate mean differences (MDs) and standardized mean differences (SMDs). Women in the MBI groups showed significant reductions in BMI, body weight, abdominal circumference, and preliminary improvements in insulin resistance (HOMA-IR; based on two studies), alongside improvements in total testosterone levels and clinical hirsutism. Although generic depression and anxiety scores did not show significant differences, disease-specific quality of life improved significantly. MBIs show potential as metabolic and endocrine modulators and may offer benefits in insulin sensitivity, weight management, and hyperandrogenism beyond mere stress reduction for women with PCOS.
Clinical relevance
Polycystic ovary syndrome (PCOS) affects a significant proportion of reproductive-age women and is characterized by a complex interplay of metabolic dysregulation, hyperandrogenism, and psychological burden, for which pharmacological options remain limited in scope and tolerability. This systematic review and meta-analysis addresses a critical gap by rigorously evaluating whether mindfulness-based interventions (MBIs)—including yoga and mindfulness meditation—can serve as evidence-based adjunctive therapies targeting multiple PCOS disease axes simultaneously. Given the growing patient interest in non-pharmacological integrative approaches and the multisystem nature of PCOS, endocrinologists and gynecologists need current evidence to counsel patients on the feasibility and magnitude of benefit from such interventions.
Key findings
1. Anthropometric outcomes: Women randomized to MBIs demonstrated statistically significant reductions in BMI, body weight, and abdominal circumference compared to controls, based on pooled data from 10 RCTs (n = 356); specific MDs and 95% CIs were not reported in the abstract. 2. Insulin resistance: Preliminary improvements in HOMA-IR were observed in the MBI groups; however, this finding is based on only two contributing studies, limiting the strength of inference and precluding robust effect size estimation. 3. Hyperandrogenism: MBIs were associated with significant improvements in total testosterone levels and clinical hirsutism scores, suggesting a potential neuroendocrine modulatory mechanism beyond generalized stress reduction. 4. Disease-specific quality of life: PCOS-specific quality of life measures improved significantly in the MBI groups, indicating meaningful patient-centered benefit that generic instruments may fail to capture. 5. Generic psychological distress: Pooled depression and anxiety scores assessed by generic instruments (e.g., non-PCOS-specific scales) did not reach statistical significance between MBI and control groups, highlighting a possible measurement sensitivity issue rather than true absence of psychological benefit. 6. Methodological scope: The meta-analysis synthesized data using mean differences (MDs) and standardized mean differences (SMDs) via Review Manager 5.3, drawing from PubMed and Cochrane Library up to January 2025; the small aggregate sample (n = 356 across 10 RCTs) warrants caution in generalizability.
Practice implications
Endocrinologists managing women with PCOS—particularly those with concurrent overweight/obesity, hyperandrogenism, or suboptimal quality of life—should consider recommending structured MBIs (e.g., yoga, mindfulness meditation programs) as adjunctive, non-pharmacological components of a multimodal treatment plan, given demonstrated benefits on anthropometric indices, testosterone levels, and hirsutism. Clinicians should preferentially use PCOS-specific quality-of-life instruments (rather than generic depression/anxiety scales) to monitor psychological response to MBIs, as generic tools may underestimate disease-relevant improvements. Until larger, adequately powered RCTs clarify the magnitude of benefit on insulin resistance (currently based on only two studies), MBIs should not replace established first-line metabolic therapies such as lifestyle modification, metformin, or inositol supplementation, but rather be integrated as a complementary strategy with individualized patient counseling.